Cargando…
Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism
A hepatic comorbidity of metabolic syndrome, known as nonalcoholic fatty liver disease (NAFLD), is increasing in prevalence in conjunction with the pandemics of obesity and diabetes. The spectrum of NAFLD ranges from simple hepatic fat accumulation to a more severe disease termed nonalcoholic steato...
Autores principales: | McCommis, Kyle S., Finck, Brian N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352854/ https://www.ncbi.nlm.nih.gov/pubmed/30686780 http://dx.doi.org/10.1016/j.jcmgh.2018.09.017 |
Ejemplares similares
-
The Hepatic Mitochondrial Pyruvate Carrier as a Regulator of Systemic Metabolism and a Therapeutic Target for Treating Metabolic Disease
por: McCommis, Kyle S., et al.
Publicado: (2023) -
Treating fatty liver disease by modulating mitochondrial pyruvate metabolism
por: Colca, Jerry R., et al.
Publicado: (2017) -
An ancestral role for the mitochondrial pyruvate carrier in glucose-stimulated insulin secretion
por: McCommis, Kyle S., et al.
Publicado: (2016) -
Identification of Novel Mitochondrial Pyruvate Carrier Inhibitors by Homology Modeling and Pharmacophore-Based Virtual Screening
por: Hegazy, Lamees, et al.
Publicado: (2022) -
Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice
por: Hodges, Wesley T., et al.
Publicado: (2021)